On Wednesday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Sonic Corp. (NASDAQ:SONC), Rovi Corporation (NASDAQ:ROVI), Neurocrine Biosciences Inc. (NASDAQ:NBIX), Coronado Biosciences, Inc. (NASDAQ:CNDO)

Sonic Corp. (NASDAQ:SONC), with shares declined -12.36%, closed at $32.13.

Rovi Corporation (NASDAQ:ROVI), with shares dropped -11.95%, settled at $18.42.

Neurocrine Biosciences Inc. (NASDAQ:NBIX), with shares dipped -11.34%, and closed at $36.37.

Coronado Biosciences, Inc. (NASDAQ:CNDO), plummeted -10.28%, and closed at $3.84.

Latest NEWS regarding these Stocks are depicted underneath:

Sonic Corp. (NASDAQ:SONC)

Sonic Corp. (SONC), declared results for the second fiscal quarter ended February 28, 2015.

Key highlights of the corporation’s second quarter of fiscal year 2015 comprised of:

• Net revenue per diluted share was $0.14 contrast with net revenue per diluted share of $0.07 in the preceding-year period; not including items outlined below, net revenue per diluted share was $0.13 in the second fiscal quarter of 2015, resulting in an 86% raise, on an adjusted basis;
• System same-store sales raised 11.5%, comprising of an 11.5% same-store sales raise at franchise drive-ins and an raise of 11.2% at corporation drive-ins;
• Corporation drive-in margins improved by 110 basis points; and
• The corporation repurchased $75 million of stock through accelerated stock repurchase transactions representing about 4% of its outstanding stock.

For the second fiscal quarter ended February 28, 2015, system same-store sales raised 11.5%, which was comprised of an 11.5% same-store sales raise at franchise drive-ins and an raise of 11.2% at corporation drive-ins.

Sonic Corp. operates and franchises a chain of quick-service drive-in restaurants in the United States. As of March 13, 2015, the corporation operated 3,517 restaurants in 44 states. It also leases signs and real estate. The corporation was founded in 1953 and is headquartered in Oklahoma City, Oklahoma.

Rovi Corporation (NASDAQ:ROVI)

Rovi Corporation (ROVI), declared the appointment of Steven Lucas to its Board of Directors, effective March 20, 2015. This appointment expands the size of the Board from six to seven directors.

As part of Rovi’s ongoing effort to augment the Corporation’s Board of Directors with expertise in key planned areas, Rovi’s Corporate Governance and Nominating Committee conducted an extensive search process with the assistance of Howard Fischer Associates, a leading professional search firm and identified, interviewed and evaluated a wide range of candidates.

Rovi Corporation provides integrated solutions for the discovery and personalization of digital entertainment to service providers and consumer electronics (CE) industry worldwide. The corporation offers interactive program guides (IPGs), an interactive listing of television or video program information that enables viewers to navigate through, sort, select, and plan video programming for viewing and recording.

Neurocrine Biosciences Inc. (NASDAQ:NBIX)

Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences Inc. (NBIX), presented at the Barclays Global Healthcare Conference in Miami, on March 10.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The corporation’s products in clinical development stage comprise elagolix, which is in Phase III study for endometriosis; elagolix that is in Phase IIb study for uterine fibroids; Corticotropin-Releasing Factor Receptor1 Antagonist, which is in Phase I/II study for congenital adrenal hyperplasia and stress-related disorders; and Vesicular Monoamine Transporter 2 Inhibitor (VMAT2) that is in Phase III study for movement disorders, in addition to Phase I study for tourette syndrome.

Coronado Biosciences, Inc. (NASDAQ:CNDO)

Formerly on March 19, Coronado Biosciences, Inc. (CNDO), declared the formation of a new corporation, Mustang Therapeutics, Inc. Mustang will initially focus on the preclinical and clinical development, in addition to commercialization of proprietary Chimeric Antigen Receptor (CAR-T) technology. This portfolio of CAR-T cells was developed by Dr. Stephen Forman, Director, T cell Therapeutics Research Laboratory and the Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, and Dr. Christine Brown, Associate Director, T cell Therapeutics Research Laboratory and Associate Research Professor. The deal is valued in excess of $40 million for the development of these CAR-T cells via up-front and milestone payments to City of Hope. It is anticipated that the first two CAR-T cells from this partnership will start enrollment in human clinical trials at the City of Hope this year.

Dr. Lindsay Rosenwald, Coronado Biosciences’ Chairman and CEO, commented, “The development of Chimeric Antigen Receptor T-cells for serious, refractory cancers is a burgeoning field of oncology. The engineering of patients’ immune cells to treat cancers may have a dramatic effect in cancer therapy. We are excited to have formed this partnership with the City of Hope and the laboratory of Dr. Stephen Forman.”

Coronado Biosciences, Inc. was founded in 2006 and is based in Burlington, Massachusetts. Coronado Biosciences, Inc., a biopharmaceutical corporation, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.